The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and activity of nonpegylated liposomal doxorubicin (nPLD) combined with oral metronomic cyclophosphamide (mC) as preoperative treatment for locally advanced breast cancer (BC) patients (pts).
Daniele Andreis
No relevant relationships to disclose
Daniele Giulio Generali
No relevant relationships to disclose
Chiara Foroni
No relevant relationships to disclose
Letizia Bazzola
No relevant relationships to disclose
Mariarosa Cappelletti
No relevant relationships to disclose
Vanessa Zanoni
No relevant relationships to disclose
Manuela Milani
No relevant relationships to disclose
Carla Strina
No relevant relationships to disclose
Giovanni Allevi
No relevant relationships to disclose
Sergio Aguggini
No relevant relationships to disclose
Ermenegilda Boni
No relevant relationships to disclose
Roberto Giardini
No relevant relationships to disclose
Ramona Bertoni
No relevant relationships to disclose
Alberto Bottini
No relevant relationships to disclose